Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + dexamethasone for relapsed/refractory CNS DLBCL or CNS myeloma
ACTRN12621001361897Phase 2Not yet recruiting
- Sponsor
- Australasian Myeloma Research Consortium
- Start
- Dec 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor and dexamethasone in Diffuse Large B-Cell Primary Central Nervous System Lymphoma and Central Nervous System Myeloma (CNS-MM), sponsored by Australasian Myeloma Research Consortium. Primary endpoints: Efficacy of selinexor-based treatment and Safety. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
selinexordexamethasone
03
Conditions
Diffuse Large B-Cell Primary Central Nervous System LymphomaCentral Nervous System Myeloma (CNS-MM)
Beyond the preview
Go deeper on ACTRN12621001361897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001361897.